Peter C. Brandt
CIK 1434099 · CEO · last filed 2026-05-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$109.5K
Companies
5
Total Filings
44
Lifetime Open-Market Net
$1.31M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INAB | Director | 98,690 | $1.11 | $109.5K | $200.0K | 13 | 2026-05-12 |
| Opus Genetics, Inc. (RNN) Delisted | Director | 1,250 | — | — | $171.0K | 11 | 2019-06-07 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | $201.0K | 6 | 2015-01-30 |
| EPOCRATES INC (EPOC) Delisted | CEO | 0 | — | — | $242.4K | 7 | 2013-03-13 |
| NOVEN PHARMACEUTICALS INC (NOVN) Delisted | President and CEO | 0 | $0.09 | $0 | $492.7K | 7 | 2009-08-27 |
Recent Filings · Page 4 of 5
44 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-09-08 | EPOCRATES INC (EPOC) Delisted | Buy (P) | +10,432 | $100.0K | EDGAR |
| 2011-06-20 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-08 | Opus Genetics, Inc. (RNN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-05-10 | EPOCRATES INC (EPOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-02-02 | EPOCRATES INC (EPOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-12-20 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-10-25 | Opus Genetics, Inc. (RNN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-08-27 | NOVEN PHARMACEUTICALS INC (NOVN) Delisted | Mixed | −183,333 | -$3.02M | EDGAR |
| 2009-08-21 | NOVEN PHARMACEUTICALS INC (NOVN) Delisted | U | −111,667 | -$1.84M | EDGAR |
| 2009-02-06 | NOVEN PHARMACEUTICALS INC (NOVN) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.